Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
about
Polymorph Impact on the Bioavailability and Stability of Poorly Soluble DrugsNon-Covalent Derivatives: Cocrystals and EutecticsDrug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and ChallengesSmall-Scale Assays for Studying Dissolution of Pharmaceutical Cocrystals for Oral Administration.The Structure, Thermodynamics and Solubility of Organic Crystals from Simulation with a Polarizable Force Field.Structures of four polymorphs of the pesticide dithianon solved from X-ray powder diffraction data.Preparation, characterization, and evaluation of dipfluzine-benzoic acid co-crystals with improved physicochemical properties.Acyclic CB[n]-type molecular containers: effect of solubilizing group on their function as solubilizing excipients.New metastable form of glibenclamide prepared by redispersion from ternary solid dispersions containing polyvinylpyrrolidone-K30 and sodium lauryl sulfate.Single-crystal X-ray diffraction and NMR crystallography of a 1:1 cocrystal of dithianon and pyrimethanil.Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdlesFormulation of indomethacin colon targeted delivery systems using polysaccharides as carriers by applying liquisolid technique.Co-crystals: a novel approach to modify physicochemical properties of active pharmaceutical ingredients.CLSM as quantitative method to determine the size of drug crystals in a solid dispersion.Polymer-mediated anti-solvent crystallization of nitrendipine: monodispersed spherical crystals and growth mechanism.Potentials of proniosomes for improving the oral bioavailability of poorly water-soluble drugs.Fast disintegrating quercetin-loaded drug delivery systems fabricated using coaxial electrospinningAcyclic cucurbit[n]uril-type molecular containers: influence of glycoluril oligomer length on their function as solubilizing agents.A comprehensive classification and nomenclature of carboxyl-carboxyl(ate) supramolecular motifs and related catemers: implications for biomolecular systemsSynthesis of a Disulfonated Derivative of Cucurbit[7]uril and Investigations of its Ability to Solubilize Insoluble Drugs.Effects of humidity and surfaces on the melt crystallization of ibuprofenDevelopment of a validated UPLC-MS/MS method for determination of humantenmine in rat plasma and its application in pharmacokinetics and bioavailability studies.Using cocrystals to systematically modulate aqueous solubility and melting behavior of an anticancer drug.Ordered nanoporous silica as carriers for improved delivery of water insoluble drugs: a comparative study between three dimensional and two dimensional macroporous silica.Pharmaceutical Cocrystals and Their Physicochemical Properties.Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubilityBenefits of cocrystallisation in pharmaceutical materials science: an update.Cocrystallization for successful drug delivery.Impact of preformulation on drug development.Hot-melt extrusion--basic principles and pharmaceutical applications.Physical stabilization of low-molecular-weight amorphous drugs in the solid state: a material science approach.Understanding pharmaceutical polymorphic transformations I: influence of process variables and storage conditions.Integration of active pharmaceutical ingredient solid form selection and particle engineering into drug product design.Solubility prediction, solvate and cocrystal screening as tools for rational crystal engineering.Solid dispersion formulations of megestrol acetate with copovidone for enhanced dissolution and oral bioavailability.Understanding pharmaceutical polymorphic transformations II: crystallization variables and influence on dosage forms.Thermal Processing of PVP- and HPMC-Based Amorphous Solid Dispersions.A top-down technique to improve the solubility and bioavailability of aceclofenac: in vitro and in vivo studies.Why do Hydrates (Solvates) Form in Small Neutral Organic Molecules? Exploring the Crystal Form Landscapes of the Alkaloids Brucine and Strychnine.Pharmaceutical cocrystals: walking the talk.
P2860
Q26779030-F5D62B4B-6922-4468-BC5D-C7A6228C1599Q26796674-6014FA74-69A5-4F18-B3E3-BA3AC2186991Q26798105-836D3215-CDA7-460D-AEBC-B758634A3598Q30375810-33D26277-416E-4EF3-A7C2-72BCC476D276Q30416702-B9114C1C-6BB6-4388-946E-D61C4DF2A90CQ30577952-78204B2F-9E2C-494D-B770-209B7051B801Q30669947-777494B1-ACCB-460D-BB2B-1036DC26772FQ30770195-231AD3D7-B752-4A07-A9A1-5297DE7801D3Q30922111-F79024F3-2C12-4832-91EF-3806DC4345CFQ33565240-26118486-644D-4E2C-A00F-28EC0896722CQ33683206-5CAA9A66-6CDE-4D1D-A31B-33E1FE1DC93DQ33757645-D3234043-E09E-4D15-9829-3241A1C881CDQ33834542-6FC8632E-2C9B-46E5-81E7-4588804F4985Q33910031-A5EC859E-E014-466E-9FAC-036851777E93Q33958395-5DCA042E-893A-42A1-BC91-855630C638F9Q35013281-B7B3DD1B-801C-42EE-8A45-360BE4B7001CQ35031092-4F97272A-8E0F-457E-BF25-AE8446FD448BQ35196330-84C4F406-841D-44DB-B092-FC30DC4F187EQ35249755-8B7758DF-A5FD-4C9C-A193-F0048E29AF00Q35546753-ADBFC633-9372-4A4F-8359-6FF087BB2CC7Q36202469-33AA30CF-990A-4672-A474-0F8103C3DAD6Q36384678-F3141861-F17C-463D-8FC0-15FA050C50C3Q37032759-E7CEDE8E-83FC-4263-B8EF-CDAA383AB871Q37254914-327D3041-4283-4AAB-B19D-E4517ACF4C73Q37510600-D1B048F4-8038-4799-9252-330AFF838DC1Q37729847-C4597A94-8637-43FD-8416-591D85DDDBB1Q37805586-F30C54C2-C4D8-465E-8AAE-3F9B49AE15B5Q38068972-071D456B-4013-466A-8BD4-D526EB7CE7D6Q38093663-11E4D8F1-DAF0-4FFA-8219-0110CDA8D467Q38187427-CD7677E2-6D5C-41B9-96E6-362B41F24355Q38257177-2D950FDE-A932-4CA9-9DBD-48331A49217DQ38270691-004802D8-34F7-405D-999C-2E327FD741ECQ38353795-4A073402-A3C3-4A09-B3EF-5BC091AEE651Q38410146-A62F994C-8FA2-4E95-A301-BD776FAAEB46Q38475312-B47BE749-B44E-4D0A-BC3C-FF5DBDC97A00Q38543393-1B6DD475-D3CD-43EA-9262-94623326DD0CQ38619443-4C39E879-C247-407E-BC14-7AE5668A4674Q38661401-9B753D72-69BC-4C7F-9A9B-C99D3D95AEDCQ38697551-F5A747B6-9933-47EA-A873-8DA0CA3771D9Q38856202-D5E31719-46BA-41F7-BA30-5E15B97360AD
P2860
Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Crystal engineering of active ...... ubility and dissolution rates.
@en
type
label
Crystal engineering of active ...... ubility and dissolution rates.
@en
prefLabel
Crystal engineering of active ...... ubility and dissolution rates.
@en
P2093
P1476
Crystal engineering of active ...... ubility and dissolution rates.
@en
P2093
P304
P356
10.1016/J.ADDR.2007.05.011
P407
P577
2007-05-29T00:00:00Z